ODM-212
- Generic Name
- ODM-212
Two-part, First-in-Human Study on ODM-212 in Subjects with Selected Advanced Solid Tumours
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Target Recruit Count
- 315
- Registration Number
- NCT06725758
- Locations
- 🇬🇧
Royal Marsden Hospital, London, UK, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath